234 related articles for article (PubMed ID: 15576013)
21. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Umar A; Boisseau M; Yusup A; Upur H; Bégaud B; Moore N
Fundam Clin Pharmacol; 2004 Oct; 18(5):559-63. PubMed ID: 15482377
[TBL] [Abstract][Full Text] [Related]
22. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
23. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.
Woessner KM; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):339-44. PubMed ID: 15521369
[TBL] [Abstract][Full Text] [Related]
24. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
Kean WF; Buchanan WW
Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
[TBL] [Abstract][Full Text] [Related]
25. [Clinical data on COX-1 and COX-2 inhibitors: what possible alerts in pharmacovigilance?].
Larousse C; Veyrac G
Therapie; 2000; 55(1):21-8. PubMed ID: 10859997
[TBL] [Abstract][Full Text] [Related]
26. Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats.
Yokota A; Taniguchi M; Takahira Y; Tanaka A; Takeuchi K
J Pharmacol Exp Ther; 2005 Jul; 314(1):302-9. PubMed ID: 15831440
[TBL] [Abstract][Full Text] [Related]
27. COX-2 selective inhibitors and heart health.
Simon LS; White WB
Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
[TBL] [Abstract][Full Text] [Related]
28. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib.
Bagán JV; Thongprasom K; Scully C
Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219
[TBL] [Abstract][Full Text] [Related]
29. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
30. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.
Ahuja N; Singh A; Singh B
J Pharm Pharmacol; 2003 Jul; 55(7):859-94. PubMed ID: 12906745
[TBL] [Abstract][Full Text] [Related]
31. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?
Giovanni G; Giovanni P
J Nephrol; 2002; 15(5):480-8. PubMed ID: 12455713
[TBL] [Abstract][Full Text] [Related]
32. [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Lamarque D
Bull Cancer; 2004 May; 91 Spec No():S117-24. PubMed ID: 15239340
[TBL] [Abstract][Full Text] [Related]
33. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
Howard PA; Delafontaine P
J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with celecoxib and rofecoxib utilization.
Rawson NS; Nourjah P; Grosser SC; Graham DJ
Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
[TBL] [Abstract][Full Text] [Related]
35. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.
Moride Y; Ducruet T; Boivin JF; Lavoie F; Rochon S
Can J Clin Pharmacol; 2005; 12(2):e201-11. PubMed ID: 15998959
[TBL] [Abstract][Full Text] [Related]
36. COX-2 inhibitors and the heart: are all coxibs the same?
Sooriakumaran P
Postgrad Med J; 2006 Apr; 82(966):242-5. PubMed ID: 16597810
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
Fosslien E
Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani EZ; Islam K
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
[TBL] [Abstract][Full Text] [Related]
39. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
[TBL] [Abstract][Full Text] [Related]
40. Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002.
Bottone FG; Barry WT
Curr Med Res Opin; 2009 Jun; 25(6):1535-50. PubMed ID: 19453292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
